BioMarin Pharmaceutical | BMRN - Debt


BioMarin Pharmaceutical reported $604.24M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Bayer EUR 39.39B 1.31B Mar/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Insmed USD 727.89M 163.33M Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Moderna USD 734M 7M Sep/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025